[Zoledronic acid reduces risk of any new clinical fracture and risk of death after surgical repair of a low-trauma hip fracture].
Leszczyński
Piotr
P
Oddział Reumatologii i Osteoporozy, Szpital im. Józefa Strusia w Poznaniu. piotr_leszczynski@wp.pl
D000368:Aged; D000369:Aged, 80 and over; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D004164:Diphosphonates / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D005265:Femoral Neck Fractures / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D005598:Fractures, Spontaneous / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D006620:Hip Fractures / Q000188:drug therapy / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D016032:Randomized Controlled Trials as Topic; D016103:Spinal Fractures / Q000517:prevention & control; D016896:Treatment Outcome; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid
Kwas zoledronowy zmniejsza ryzyko wystepowania nowych klinicznych złamań i zmniejsza śmiertelność po osteoporotycznym złamaniu kości udowej leczonym operacyjnie.